Commercial newswire·US·
Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD
– Partnership will introduce NeuroSigma’s second-generation Monarch eTNS ® System to Firefly’s nationwide network of Evoke™ clinicians –
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Atlas Energy Corp Completes C$15.0 Million Royalty Investment and Receives Approval to Exit TSXV Sandbox
- Alpha Compute Regains Full Compliance with Nasdaq Listing Rules
- REV Commences Drill Program Targeting Helium in Northern Great Plains
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →Shared via PPN World — real-time press release intelligence.